Thursday
On The Fly
Show Hide Related Items >> <<
05/16/22 Zynerba expects cash to fund operations into second half of 2023 05/11/22 Zynerba presents long-term safety, efficacy data of Zygel 05/02/22 Zynerba presents long-term safety, efficacy data of Zygel 04/18/22 Tela Bio appoints D. Taylor Ocasio as general counsel 12/22/21 Tryp Therapeutics receives FDA confirmation to proceed with Phase 2a study 05/12/22 Tilray announces expansion of Good Supply's cannabis portfolio 04/12/22 HEXO, Tilray enter agreement for strategic alliance 04/12/22 Tilray enters agreement with HEXO related to Senior Secured Convertible Note 04/06/22 Tilray subsidiary Manitoba Harvest partners with Whole Foods Market 03/22/22 Tilt appoints Lynn Ricci as VP, investor relations, corporate communications 12/28/21 Trulieve appoints Steve White as president, Nicole Stanton as general counsel 12/28/21 Trulieve Cannabis acquires PurpleMed Healting Center in Arizona 11/29/21 Trulieve Cannabis issues first inaugural ESG report RLMD Relmada Therapeutics 04/29/22 Relmada Therapeutics announces publication of REL-1017 preclinical study 02/23/22 Relmada Therapeutics announces results from REL-1017 HAP study 12/22/21 Relmada Therapeutics: REL-1017 Phase 2 results published in AJOP IGC India Globalization Capital 12/08/21 India Globalization Capital says IGC-AD1 ph 1 trial provided 'valuable insight' 12/02/21 India Globalization Capital presents findings from Phase 1 trial of IGC-AD1 GTBIF Green Thumb Industries 05/02/22 Green Thumb announces internet availability of proxy materials for 2022 meeting 04/11/22 Green Thumb Industries to open RISE Mankato on April 14 03/11/22 Green Thumb Industries announces departure of Moore from board of directors 02/08/22 Green Thumb Industries appoints Dorri McWhorter to board of directors 02/28/22 Goodness Growth launches full line of cannabis flower in Minnesota 02/01/22 Verano Holdings to acquire Goodness Growth in $413M all-share transaction 03/08/22 CV Sciences adds +PlusCBD Relief Softgels to its Wellness line 01/11/22 CV Sciences launches +PlusCBD Pain Relief topicals 01/05/22 CV Sciences announces new distribution agreement with GNC 01/06/22 CannTrust reports implementation of CCAA plan, settlement of lawsuits 03/21/22 Cronos Group founder Mike Gorenstein returns as CEO 03/01/22 Cronos Group announces planned exit of Peace Naturals Campus in Ontario 02/18/22 Cronos Group announces strategic realignment for $20M-$25M in savings 02/18/22 Cronos Group completes Audit Committee evaluation 05/09/22 Compass Pathways to fund study of COMP360 psilocybin in autistic adults 05/03/22 Compass Pathways announces data on COMP360 psilocybin therapy 04/20/22 Compass Pathways partners with One Mind for Rising Star Awards 03/24/22 Compass Pathways, partners to launch psychedelic research facility 05/18/22 Canopy Growth announces plans to acquire Jetty Extracts 04/26/22 Canopy Growth expects to generate savings of $100M-$150M within 12-18 months 04/26/22 Canopy Growth announces cost reduction initiatives including headcount reduction 03/31/22 Canopy Growth appoints Judy Hong as CFO, Jonathan Di Tosto as COO 03/30/22 Atai Life Sciences reports Q4 net loss $88.9M vs. $86.6M a year ago 02/01/22 IntelGenx receives third loan tranche from Atai Life Sciences 01/27/22 Atai Life Sciences to partner with Dalriada 01/12/22 atai Life Sciences' IND for PCN-101 approved by FDA 05/18/22 Aurora Cannabis receives EU-GMP certification for facility in Germany 05/12/22 Aurora Cannabis raises expense savings target to C$150M-C$170M 03/22/22 Aurora Cannabis to acquire Thrive Cannabis for $38M 02/10/22 Aurora Cannabis reaffirms goal of adjusted EBITDA profitability by 1H2023 05/12/22 Canaccord Goodness Growth price target lowered to C$3.50 from C$4 at Canaccord 04/01/22 Alliance Global Partners Senate remains the hurdle for MORE Act, says Alliance Global Partners 02/01/22 Craig-Hallum Goodness Growth downgraded to Hold from Buy at Craig-Hallum 11/11/21 Canaccord Goodness Growth price target lowered to C$2.75 from C$4.50 at Canaccord 06/25/21 Alliance Global Partners Cannabis selloff brings buying opportunities, says Alliance Global 05/12/22 Alliance Global Partners Trulieve Cannabis price target lowered to C$50 from C$60 at Alliance Global Partners 03/31/22 Canaccord Trulieve Cannabis price target lowered to C$65 from C$70 at Canaccord 03/30/22 Alliance Global Partners Trulieve Cannabis price target lowered to C$60 from C$76 at Alliance Global Partners 05/02/22 Alliance Global Partners Tilray price target lowered to $5.50 from $8 at Alliance Global Partners 04/20/22 Barclays Tilray price target lowered to $4.50 from $8.50 at Barclays 04/06/22 MKM Partners Tilray margins contracted despite cost savings, says MKM Partners 04/06/22 Benchmark Tilray fiscal Q3 results 'disappointing,' says Benchmark IGC India Globalization Capital GTBIF Green Thumb Industries 05/05/22 Alliance Global Partners Green Thumb price target lowered to C$38 from C$40 at Alliance Global 05/05/22 Craig-Hallum Green Thumb Industries price target lowered to $25 from $35 at Craig-Hallum 05/05/22 Needham Green Thumb Industries price target lowered to $26 from $33 at Needham 05/11/22 CIBC CIBC upgrades Cronos to buy on 'multiple reasons for optimism' 05/11/22 Canaccord Cronos upgraded to Hold on operational improvements at Canaccord 05/11/22 CIBC Cronos Group upgraded to Outperformer from Neutral at CIBC 05/11/22 Canaccord Cronos Group upgraded to Hold from Sell at Canaccord 05/20/22 Alliance Global Partners Canopy Growth price target lowered to C$8 from C$11 at Alliance Global Partners 04/04/22 Morgan Stanley Constellation Brands price target lowered to $294 from $299 at Morgan Stanley 03/22/22 Barclays Canopy Growth downgraded to Underweight from Equal Weight at Barclays 05/16/22 CIBC Aurora Cannabis price target lowered to C$3.75 from C$6.50 at CIBC 05/13/22 Cantor Fitzgerald Aurora Cannabis price target lowered to C$3.90 from C$7.60 at Cantor Fitzgerald 02/11/22 Cantor Fitzgerald Aurora Cannabis price target lowered to C$7.60 from C$10.75 at Cantor Fitzgerald RLMD Relmada Therapeutics 05/09/22 Oppenheimer Relmada Therapeutics price target lowered to $64 from $75 at Oppenheimer 12/20/21 SVB Leerink Relmada Therapeutics price target lowered to $42 from $50 at SVB Leerink 11/17/21 Mizuho Relmada Therapeutics initiated with a Buy at Mizuho 09/30/21 Jefferies Jefferies says Street discounting importance of Relmada's Phase 2 mono MDD study 02/28/22 Canaccord Compass Pathways price target lowered to $78 from $80 at Canaccord 11/11/21 Roth Capital Atai Life Sciences initiated with a Buy at Roth Capital 11/09/21 Citi Citi says Compass Pathways selloff overdone, ups price target to $70 11/09/21 Cantor Fitzgerald Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald 05/17/22 Citi Atai Life Sciences price target lowered to $22 from $26 at Citi 04/01/22 Canaccord Atai Life Sciences price target lowered to $27 from $28 at Canaccord 03/31/22 RBC Capital Atai Life Sciences price target lowered to $9 from $12 at RBC Capital 11/30/21 Fly Intel: Top five analyst initiations 08/26/21 Ladenburg Tryp Therapeutics initiated with a Buy at Ladenburg 05/16/22 Zynerba reports Q1 EPS (21c), consensus (23c) 03/01/22 Zynerba reports Q4 EPS (22c), consensus (26c) 04/06/22 Tilray reports Q3 EPS 9c vs. ($1.03) last year 01/10/22 Tilray reports Q2 revenue $155M vs. $129M last year 05/12/22 Trulieve Cannabis reiterates 2022 revenue view $1.3B-$1.4B 05/12/22 Trulieve Cannabis reports Q1 adjusted EPS 1c vs. 30c last year RLMD Relmada Therapeutics 05/05/22 Relmada Therapeutics reports Q1 EPS ($1.40), consensus ($1.27) 03/23/22 Relmada Therapeutics reports Q4 EPS ($1.80), consensus ($1.83) GTBIF Green Thumb Industries 03/01/22 Green Thumb Industries reports Q4 EPS 10c vs. 11c last year 05/16/22 CV Sciences reports Q1 EPS (3c) vs. (2c) last year 05/10/22 Cronos Group reports Q1 EPS (9c), consensus (8c) 03/01/22 Cronos Group reports 2021 EPS ($1.07), consensus (47c) 02/18/22 Cronos Group reports Q3 EPS 21c, consensus (10c) 05/10/22 Compass Pathways reports Q1 EPS (50c), consensus (67c) 02/24/22 Compass Pathways reports Q4 EPS (61c), consensus (50c) 04/07/22 Constellation Brands reports Q4 comparable EPS ex-Canopy losses $2.55 02/09/22 Canopy Growth reports Q3 EPS (C$0.28) vs. (C$2.43) a year ago 05/16/22 Atai Life Sciences reports Q1 EPS (24c), consensus (24c) 05/12/22 Aurora Cannabis reports Q3 revenue C$50.43M vs. C$55.16M a year ago 02/10/22 Aurora Cannabis reports Q2 adjusted EBITDA (C$9M) vs. (C$11.5) in Q1 02/10/22 Aurora Cannabis reports Q2 revenue C$60.6M, vs. C$67.67M a year ago 01/04/22 Aurora Cannabis to deliver C$10M cannabis shipment to Israel
Over a week ago
On The Fly
Show Hide Related Items >> <<
05/11/22 Zynerba presents long-term safety, efficacy data of Zygel 05/02/22 Zynerba presents long-term safety, efficacy data of Zygel 04/18/22 Tela Bio appoints D. Taylor Ocasio as general counsel 02/28/22 Zynerba announces EC grants orphan drug designation for Zygel 05/12/22 Tilray announces expansion of Good Supply's cannabis portfolio 04/12/22 HEXO, Tilray enter agreement for strategic alliance 04/12/22 Tilray enters agreement with HEXO related to Senior Secured Convertible Note 04/06/22 Tilray subsidiary Manitoba Harvest partners with Whole Foods Market 03/22/22 Tilt appoints Lynn Ricci as VP, investor relations, corporate communications 12/28/21 Trulieve appoints Steve White as president, Nicole Stanton as general counsel 12/28/21 Trulieve Cannabis acquires PurpleMed Healting Center in Arizona 11/29/21 Trulieve Cannabis issues first inaugural ESG report RLMD Relmada Therapeutics 04/29/22 Relmada Therapeutics announces publication of REL-1017 preclinical study 02/23/22 Relmada Therapeutics announces results from REL-1017 HAP study 12/22/21 Relmada Therapeutics: REL-1017 Phase 2 results published in AJOP NLCP NewLake Capital Partners 05/09/22 NewLake Capital Partners enters revolving credit facility 04/06/22 NewLake Capital Partners acquires cultivation property in Missouri for $34M 12/21/21 NewLake Capital Partners acquires Missouri property for $21.1M investment 12/16/21 NewLake Capital Partners raises quarterly dividend 29% to 31c per share IGC India Globalization Capital 12/08/21 India Globalization Capital says IGC-AD1 ph 1 trial provided 'valuable insight' 12/02/21 India Globalization Capital presents findings from Phase 1 trial of IGC-AD1 GTBIF Green Thumb Industries 05/02/22 Green Thumb announces internet availability of proxy materials for 2022 meeting 04/11/22 Green Thumb Industries to open RISE Mankato on April 14 03/11/22 Green Thumb Industries announces departure of Moore from board of directors 02/08/22 Green Thumb Industries appoints Dorri McWhorter to board of directors 02/28/22 Goodness Growth launches full line of cannabis flower in Minnesota 02/01/22 Verano Holdings to acquire Goodness Growth in $413M all-share transaction 03/08/22 CV Sciences adds +PlusCBD Relief Softgels to its Wellness line 01/11/22 CV Sciences launches +PlusCBD Pain Relief topicals 01/05/22 CV Sciences announces new distribution agreement with GNC 11/15/21 CV Sciences announces convertible note financing 01/06/22 CannTrust reports implementation of CCAA plan, settlement of lawsuits 03/21/22 Cronos Group founder Mike Gorenstein returns as CEO 03/01/22 Cronos Group announces planned exit of Peace Naturals Campus in Ontario 02/18/22 Cronos Group announces strategic realignment for $20M-$25M in savings 02/18/22 Cronos Group completes Audit Committee evaluation 05/09/22 Compass Pathways to fund study of COMP360 psilocybin in autistic adults 05/03/22 Compass Pathways announces data on COMP360 psilocybin therapy 04/20/22 Compass Pathways partners with One Mind for Rising Star Awards 03/24/22 Compass Pathways, partners to launch psychedelic research facility 04/26/22 Canopy Growth expects to generate savings of $100M-$150M within 12-18 months 04/26/22 Canopy Growth announces cost reduction initiatives including headcount reduction 03/31/22 Canopy Growth appoints Judy Hong as CFO, Jonathan Di Tosto as COO 03/22/22 Canopy Growth announces results from trial using CBD on menstrual symptoms 03/30/22 Atai Life Sciences reports Q4 net loss $88.9M vs. $86.6M a year ago 02/01/22 IntelGenx receives third loan tranche from Atai Life Sciences 01/27/22 Atai Life Sciences to partner with Dalriada 01/12/22 atai Life Sciences' IND for PCN-101 approved by FDA 03/22/22 Aurora Cannabis to acquire Thrive Cannabis for $38M 02/10/22 Aurora Cannabis reaffirms goal of adjusted EBITDA profitability by 1H2023 02/03/22 Aurora Cannabis' Reliva launches new product line, KG7 12/14/21 Aurora Cannabis and 22nd Century sign license agreement with Cronos Group RLMD Relmada Therapeutics 05/09/22 Oppenheimer Relmada Therapeutics price target lowered to $64 from $75 at Oppenheimer 12/20/21 SVB Leerink Relmada Therapeutics price target lowered to $42 from $50 at SVB Leerink 11/17/21 Mizuho Relmada Therapeutics initiated with a Buy at Mizuho 09/30/21 Jefferies Jefferies says Street discounting importance of Relmada's Phase 2 mono MDD study 02/28/22 Canaccord Compass Pathways price target lowered to $78 from $80 at Canaccord 11/11/21 Roth Capital Atai Life Sciences initiated with a Buy at Roth Capital 11/09/21 Citi Citi says Compass Pathways selloff overdone, ups price target to $70 11/09/21 Cantor Fitzgerald Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald 04/01/22 Canaccord Atai Life Sciences price target lowered to $27 from $28 at Canaccord 03/31/22 RBC Capital Atai Life Sciences price target lowered to $9 from $12 at RBC Capital 11/30/21 Fly Intel: Top five analyst initiations 11/30/21 Maxim Atai Life Sciences initiated with a Buy at Maxim 04/01/22 Alliance Global Partners Senate remains the hurdle for MORE Act, says Alliance Global Partners 06/25/21 Alliance Global Partners Cannabis selloff brings buying opportunities, says Alliance Global 05/12/22 Alliance Global Partners Trulieve Cannabis price target lowered to C$50 from C$60 at Alliance Global Partners 03/31/22 Canaccord Trulieve Cannabis price target lowered to C$65 from C$70 at Canaccord 03/30/22 Alliance Global Partners Trulieve Cannabis price target lowered to C$60 from C$76 at Alliance Global Partners 05/02/22 Alliance Global Partners Tilray price target lowered to $5.50 from $8 at Alliance Global Partners 04/20/22 Barclays Tilray price target lowered to $4.50 from $8.50 at Barclays 04/06/22 MKM Partners Tilray margins contracted despite cost savings, says MKM Partners 04/06/22 Benchmark Tilray fiscal Q3 results 'disappointing,' says Benchmark IGC India Globalization Capital GTBIF Green Thumb Industries 05/05/22 Alliance Global Partners Green Thumb price target lowered to C$38 from C$40 at Alliance Global 05/05/22 Craig-Hallum Green Thumb Industries price target lowered to $25 from $35 at Craig-Hallum 05/05/22 Needham Green Thumb Industries price target lowered to $26 from $33 at Needham 05/12/22 Canaccord Goodness Growth price target lowered to C$3.50 from C$4 at Canaccord 02/01/22 Craig-Hallum Goodness Growth downgraded to Hold from Buy at Craig-Hallum 11/11/21 Canaccord Goodness Growth price target lowered to C$2.75 from C$4.50 at Canaccord 05/11/22 CIBC CIBC upgrades Cronos to buy on 'multiple reasons for optimism' 05/11/22 Canaccord Cronos upgraded to Hold on operational improvements at Canaccord 05/11/22 CIBC Cronos Group upgraded to Outperformer from Neutral at CIBC 05/11/22 Canaccord Cronos Group upgraded to Hold from Sell at Canaccord 04/04/22 Morgan Stanley Constellation Brands price target lowered to $294 from $299 at Morgan Stanley 03/22/22 Barclays Canopy Growth downgraded to Underweight from Equal Weight at Barclays 03/01/22 Barclays Canopy Growth price target lowered to $9 from $14 at Barclays 05/13/22 Cantor Fitzgerald Aurora Cannabis price target lowered to C$3.90 from C$7.60 at Cantor Fitzgerald 02/11/22 Cantor Fitzgerald Aurora Cannabis price target lowered to C$7.60 from C$10.75 at Cantor Fitzgerald 02/03/22 CIBC Aurora Cannabis price target lowered to C$6.50 from C$9.25 at CIBC NLCP NewLake Capital Partners 03/21/22 Ladenburg NewLake Capital price target lowered to $39.50 from $44 at Ladenburg 09/08/21 Compass Point NewLake Capital Partners initiated with a Buy at Compass Point 09/07/21 Ladenburg NewLake Capital Partners initiated with a Buy at Ladenburg 03/01/22 Zynerba reports Q4 EPS (22c), consensus (26c) 11/15/21 Zynerba reports Q3 EPS (26c), consensus (25c) 04/06/22 Tilray reports Q3 EPS 9c vs. ($1.03) last year 01/10/22 Tilray reports Q2 revenue $155M vs. $129M last year 05/12/22 Trulieve Cannabis reiterates 2022 revenue view $1.3B-$1.4B 05/12/22 Trulieve Cannabis reports Q1 adjusted EPS 1c vs. 30c last year RLMD Relmada Therapeutics 05/05/22 Relmada Therapeutics reports Q1 EPS ($1.40), consensus ($1.27) 03/23/22 Relmada Therapeutics reports Q4 EPS ($1.80), consensus ($1.83) NLCP NewLake Capital Partners 03/17/22 NewLake Capital Partners reports Q4 adjusted FFO 32c vs. 63c last year GTBIF Green Thumb Industries 03/01/22 Green Thumb Industries reports Q4 EPS 10c vs. 11c last year 11/15/21 CV Sciences reports Q3 EPS 0c vs. (3c) last year 05/10/22 Cronos Group reports Q1 EPS (9c), consensus (8c) 03/01/22 Cronos Group reports 2021 EPS ($1.07), consensus (47c) 02/18/22 Cronos Group reports Q3 EPS 21c, consensus (10c) 05/10/22 Compass Pathways reports Q1 EPS (50c), consensus (67c) 02/24/22 Compass Pathways reports Q4 EPS (61c), consensus (50c) 04/07/22 Constellation Brands reports Q4 comparable EPS ex-Canopy losses $2.55 02/09/22 Canopy Growth reports Q3 EPS (C$0.28) vs. (C$2.43) a year ago 11/15/21 Atai Life Sciences reports Q3 EPS (21c), consensus (20c) 02/10/22 Aurora Cannabis reports Q2 adjusted EBITDA (C$9M) vs. (C$11.5) in Q1 02/10/22 Aurora Cannabis reports Q2 revenue C$60.6M, vs. C$67.67M a year ago 01/04/22 Aurora Cannabis to deliver C$10M cannabis shipment to Israel
Earnings
Cash and cash equivalents…
Cash and cash equivalents were $243.7 million as of 31 March 2022 compared with $273.2 million as of December 31, 2021.
Show Hide Related Items >> <<
05/09/22 Compass Pathways to fund study of COMP360 psilocybin in autistic adults 05/03/22 Compass Pathways announces data on COMP360 psilocybin therapy 04/20/22 Compass Pathways partners with One Mind for Rising Star Awards 03/24/22 Compass Pathways, partners to launch psychedelic research facility 02/28/22 Canaccord Compass Pathways price target lowered to $78 from $80 at Canaccord 11/11/21 Roth Capital Atai Life Sciences initiated with a Buy at Roth Capital 11/09/21 Citi Citi says Compass Pathways selloff overdone, ups price target to $70 11/09/21 Cantor Fitzgerald Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald 02/24/22 Compass Pathways reports Q4 EPS (61c), consensus (50c) 05/05/22 Here's What You Missed in Cannabis, Psychedelics This Week 04/28/22 Here's What You Missed in Cannabis This Week 04/21/22 Rising High: Exclusive talk with psychedelics organization MAPS PBC 04/14/22 Here's What You Missed in Cannabis This Week
Hot Stocks
COMPASS Pathways…
COMPASS Pathways announced it will be funding an investigator-initiated study that will use COMP360 psilocybin to explore how psilocybin affects specific brain pathways in autistic adults. This will be the first ever mechanistic study of psilocybin in autistic adults. The double-blind, randomized, placebo-controlled study will investigate whether there is a difference in the function of serotonin brain networks in autistic and non-autistic adults. The researchers will use a range of imaging techniques and behavioural tasks to examine how the serotonin system is modulated by COMP360 psilocybin. It is an investigator-initiated exploratory study that will take place at the Institute of Psychiatry, Psychology & Neuroscience at King's College London. The study is co-sponsored by King's IoPPN and South London and Maudsley NHS Foundation Trust. It will enroll 70 adult participants, including 40 autistic people and 30 non-autistic people. The study is led by Professor Grainne McAlonan, Professor of Translational Neuroscience at King's IoPPN, and conducted by Tobias Whelan, PhD student at King's and Research Scientist at COMPASS Pathways.
Show Hide Related Items >> <<
05/03/22 Compass Pathways announces data on COMP360 psilocybin therapy 04/20/22 Compass Pathways partners with One Mind for Rising Star Awards 03/24/22 Compass Pathways, partners to launch psychedelic research facility 01/19/22 Compass Pathways announces results from survey conducted with Sermo on TRD 02/28/22 Canaccord Compass Pathways price target lowered to $78 from $80 at Canaccord 11/11/21 Roth Capital Atai Life Sciences initiated with a Buy at Roth Capital 11/09/21 Citi Citi says Compass Pathways selloff overdone, ups price target to $70 11/09/21 Cantor Fitzgerald Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald 02/24/22 Compass Pathways reports Q4 EPS (61c), consensus (50c) 11/09/21 Compass Pathways reports Q3 EPS (38c), consensus (49c) 05/05/22 Here's What You Missed in Cannabis, Psychedelics This Week 04/28/22 Here's What You Missed in Cannabis This Week 04/21/22 Rising High: Exclusive talk with psychedelics organization MAPS PBC 04/14/22 Here's What You Missed in Cannabis This Week 11/09/21 Unusually active option classes on open November 9th
On The Fly
Show Hide Related Items >> <<
05/02/22 Zynerba presents long-term safety, efficacy data of Zygel 04/18/22 Tela Bio appoints D. Taylor Ocasio as general counsel 02/28/22 Zynerba announces EC grants orphan drug designation for Zygel 02/28/22 Zynerba announces completion of enrollment in Phase 2 trial of Zygel 05/05/22 Wesana Health to conduct strategic review of care delivery division 03/22/22 Wesana Health announces data from animal study of psilocybin 03/14/22 Wesana Health announces feedback from pre-IND meeting on SANA-013 02/02/22 Jones Soda, Wesana Health, Mike Tyson partner to launch nootropic supplement 04/12/22 HEXO, Tilray enter agreement for strategic alliance 04/12/22 Tilray enters agreement with HEXO related to Senior Secured Convertible Note 04/06/22 Tilray subsidiary Manitoba Harvest partners with Whole Foods Market 04/05/22 Tilray announces Solei brand launches cannabis edible in Quebec 03/22/22 Tilt appoints Lynn Ricci as VP, investor relations, corporate communications 12/28/21 Trulieve appoints Steve White as president, Nicole Stanton as general counsel 12/28/21 Trulieve Cannabis acquires PurpleMed Healting Center in Arizona 11/29/21 Trulieve Cannabis issues first inaugural ESG report RLMD Relmada Therapeutics 04/29/22 Relmada Therapeutics announces publication of REL-1017 preclinical study 02/23/22 Relmada Therapeutics announces results from REL-1017 HAP study 12/22/21 Relmada Therapeutics: REL-1017 Phase 2 results published in AJOP IGC India Globalization Capital 12/08/21 India Globalization Capital says IGC-AD1 ph 1 trial provided 'valuable insight' 12/02/21 India Globalization Capital presents findings from Phase 1 trial of IGC-AD1 GTBIF Green Thumb Industries 05/02/22 Green Thumb announces internet availability of proxy materials for 2022 meeting 04/11/22 Green Thumb Industries to open RISE Mankato on April 14 03/11/22 Green Thumb Industries announces departure of Moore from board of directors 02/08/22 Green Thumb Industries appoints Dorri McWhorter to board of directors 02/28/22 Goodness Growth launches full line of cannabis flower in Minnesota 02/01/22 Verano Holdings to acquire Goodness Growth in $413M all-share transaction 05/04/22 Entourage Health partners with Pineapple Express for same-day cannabis delivery 05/03/22 Entourage Health reaffirms preliminary 2021 revenue C$55.2M 03/25/22 Entourage Health launches 'Joints for Justice' retail campaign 03/24/22 Entourage Health updates timing for Q4, 2021 financials 03/08/22 CV Sciences adds +PlusCBD Relief Softgels to its Wellness line 01/11/22 CV Sciences launches +PlusCBD Pain Relief topicals 01/05/22 CV Sciences announces new distribution agreement with GNC 11/15/21 CV Sciences announces convertible note financing 01/06/22 CannTrust reports implementation of CCAA plan, settlement of lawsuits 03/21/22 Cronos Group founder Mike Gorenstein returns as CEO 03/01/22 Cronos Group announces planned exit of Peace Naturals Campus in Ontario 02/18/22 Cronos Group announces strategic realignment for $20M-$25M in savings 02/18/22 Cronos Group completes Audit Committee evaluation 05/03/22 Compass Pathways announces data on COMP360 psilocybin therapy 04/20/22 Compass Pathways partners with One Mind for Rising Star Awards 03/24/22 Compass Pathways, partners to launch psychedelic research facility 01/19/22 Compass Pathways announces results from survey conducted with Sermo on TRD 04/26/22 Canopy Growth expects to generate savings of $100M-$150M within 12-18 months 04/26/22 Canopy Growth announces cost reduction initiatives including headcount reduction 03/31/22 Canopy Growth appoints Judy Hong as CFO, Jonathan Di Tosto as COO 03/22/22 Canopy Growth announces results from trial using CBD on menstrual symptoms 03/30/22 Atai Life Sciences reports Q4 net loss $88.9M vs. $86.6M a year ago 02/01/22 IntelGenx receives third loan tranche from Atai Life Sciences 01/27/22 Atai Life Sciences to partner with Dalriada 01/12/22 atai Life Sciences' IND for PCN-101 approved by FDA 03/22/22 Aurora Cannabis to acquire Thrive Cannabis for $38M 02/10/22 Aurora Cannabis reaffirms goal of adjusted EBITDA profitability by 1H2023 02/03/22 Aurora Cannabis' Reliva launches new product line, KG7 12/14/21 Aurora Cannabis and 22nd Century sign license agreement with Cronos Group GTBIF Green Thumb Industries 05/05/22 Alliance Global Partners Green Thumb price target lowered to C$38 from C$40 at Alliance Global 05/05/22 Craig-Hallum Green Thumb Industries price target lowered to $25 from $35 at Craig-Hallum 05/05/22 Needham Green Thumb Industries price target lowered to $26 from $33 at Needham 04/01/22 Alliance Global Partners Senate remains the hurdle for MORE Act, says Alliance Global Partners 11/18/21 Canaccord Entourage Health price target lowered to C$0.40 from C$0.60 at Canaccord 11/17/21 Canaccord Entourage Health price target lowered to C$0.40 from C$0.60 at Canaccord FFLWF Fire & Flower Holdings 04/28/22 Stifel Fire & Flower Holdings price target lowered to C$8.50 from C$12 at Stifel 12/15/21 Stifel Fire & Flower Holdings downgraded to Speculative Buy from Buy at Stifel 11/23/21 Cantor Fitzgerald Fire & Flower Holdings initiated with an Overweight at Cantor Fitzgerald 11/22/21 Cantor Fitzgerald Fire & Flower initiated with an Overweight at Cantor Fitzgerald 02/28/22 Canaccord Compass Pathways price target lowered to $78 from $80 at Canaccord 11/11/21 Roth Capital Atai Life Sciences initiated with a Buy at Roth Capital 11/09/21 Citi Citi says Compass Pathways selloff overdone, ups price target to $70 11/09/21 Cantor Fitzgerald Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald 04/01/22 Stifel Wesana Health initiated with a Speculative Buy at Stifel 05/02/22 Alliance Global Partners Tilray price target lowered to $5.50 from $8 at Alliance Global Partners 04/20/22 Barclays Tilray price target lowered to $4.50 from $8.50 at Barclays 04/06/22 MKM Partners Tilray margins contracted despite cost savings, says MKM Partners 04/06/22 Benchmark Tilray fiscal Q3 results 'disappointing,' says Benchmark 02/11/22 Cantor Fitzgerald Aurora Cannabis price target lowered to C$7.60 from C$10.75 at Cantor Fitzgerald 02/03/22 CIBC Aurora Cannabis price target lowered to C$6.50 from C$9.25 at CIBC 11/11/21 Canaccord Aurora Cannabis price target lowered to C$6 from C$6.50 at Canaccord 06/25/21 Alliance Global Partners Cannabis selloff brings buying opportunities, says Alliance Global 04/04/22 Morgan Stanley Constellation Brands price target lowered to $294 from $299 at Morgan Stanley 03/22/22 Barclays Canopy Growth downgraded to Underweight from Equal Weight at Barclays 03/01/22 Barclays Canopy Growth price target lowered to $9 from $14 at Barclays 03/22/22 Barclays Cronos Group upgraded to Equal Weight from Underweight at Barclays 03/21/22 Stifel Stifel takes neutral overall view of Cronos' CEO transition 03/07/22 Piper Sandler Cronos Group price target lowered to $3 from $4 at Piper Sandler 02/01/22 Craig-Hallum Goodness Growth downgraded to Hold from Buy at Craig-Hallum 11/11/21 Canaccord Goodness Growth price target lowered to C$2.75 from C$4.50 at Canaccord IGC India Globalization Capital 03/31/22 Canaccord Trulieve Cannabis price target lowered to C$65 from C$70 at Canaccord 03/30/22 Alliance Global Partners Trulieve Cannabis price target lowered to C$60 from C$76 at Alliance Global Partners 03/29/22 Cantor Fitzgerald Trulieve Cannabis price target lowered to $60 from $72 at Cantor Fitzgerald 05/06/21 Cantor Fitzgerald Zynerba price target raised to $8 from $6 at Cantor Fitzgerald RLMD Relmada Therapeutics 12/20/21 SVB Leerink Relmada Therapeutics price target lowered to $42 from $50 at SVB Leerink 11/17/21 Mizuho Relmada Therapeutics initiated with a Buy at Mizuho 09/30/21 Jefferies Jefferies says Street discounting importance of Relmada's Phase 2 mono MDD study 07/28/21 Truist Relmada Therapeutics price target raised to $90 from $75 at Truist 04/01/22 Canaccord Atai Life Sciences price target lowered to $27 from $28 at Canaccord 03/31/22 RBC Capital Atai Life Sciences price target lowered to $9 from $12 at RBC Capital 11/30/21 Fly Intel: Top five analyst initiations 11/30/21 Maxim Atai Life Sciences initiated with a Buy at Maxim 03/01/22 Zynerba reports Q4 EPS (22c), consensus (26c) 11/15/21 Zynerba reports Q3 EPS (26c), consensus (25c) 04/06/22 Tilray reports Q3 EPS 9c vs. ($1.03) last year 01/10/22 Tilray reports Q2 revenue $155M vs. $129M last year RLMD Relmada Therapeutics 03/23/22 Relmada Therapeutics reports Q4 EPS ($1.80), consensus ($1.83) 11/11/21 Relmada Therapeutics reports Q3 EPS ($2.44), consensus ($1.60) GTBIF Green Thumb Industries 03/01/22 Green Thumb Industries reports Q4 EPS 10c vs. 11c last year 04/22/22 Entourage Health reaffirms preliminary 2021 revenue C$54.8M 02/11/22 Entourage Health reports 2021 revenue C$54.8M, up 54% y-o-y 11/16/21 Entourage Health reports Q3 revenue C$14.9M vs. C$7.74M last year 11/15/21 CV Sciences reports Q3 EPS 0c vs. (3c) last year 03/01/22 Cronos Group reports 2021 EPS ($1.07), consensus (47c) 02/18/22 Cronos Group reports Q3 EPS 21c, consensus (10c) 02/24/22 Compass Pathways reports Q4 EPS (61c), consensus (50c) 11/09/21 Compass Pathways reports Q3 EPS (38c), consensus (49c) 04/07/22 Constellation Brands reports Q4 comparable EPS ex-Canopy losses $2.55 02/09/22 Canopy Growth reports Q3 EPS (C$0.28) vs. (C$2.43) a year ago 11/15/21 Atai Life Sciences reports Q3 EPS (21c), consensus (20c) 02/10/22 Aurora Cannabis reports Q2 adjusted EBITDA (C$9M) vs. (C$11.5) in Q1 02/10/22 Aurora Cannabis reports Q2 revenue C$60.6M, vs. C$67.67M a year ago 01/04/22 Aurora Cannabis to deliver C$10M cannabis shipment to Israel 11/09/21 Aurora Cannabis reports Q1 revenue C$60.1M vs. C$67.59M last year
Over a month ago
Hot Stocks
COMPASS Pathways…
COMPASS Pathways announced it is partnering with One Mind, a leading mental health research non-profit based in California, to sponsor three "2022 One Mind - COMPASS Rising Stars Awards". The One Mind Rising Star Awards are given each year to promising early career investigators who are pursuing research with the potential to dramatically advance the understanding and treatment of mental illnesses, and to improve patient outcomes. A Request for Applications was issued by One Mind today and up to three winners will be selected by One Mind's Scientific Advisory Board through a competitive process. The winners, to be announced in September 2022, will each receive a $300,000 research grant sponsored by COMPASS over three years. They will also be eligible to participate in select leadership development and entrepreneurship opportunities through the One Mind Rising Star Development Program offered by One Mind.
Show Hide Related Items >> <<
03/24/22 Compass Pathways, partners to launch psychedelic research facility 01/19/22 Compass Pathways announces results from survey conducted with Sermo on TRD 01/04/22 Compass Pathways announces results from phase I study on COMP360 12/17/21 Compass Pathways to be added to Nasdaq Biotechnology Index 02/28/22 Canaccord Compass Pathways price target lowered to $78 from $80 at Canaccord 11/11/21 Roth Capital Atai Life Sciences initiated with a Buy at Roth Capital 11/09/21 Citi Citi says Compass Pathways selloff overdone, ups price target to $70 11/09/21 Cantor Fitzgerald Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald 02/24/22 Compass Pathways reports Q4 EPS (61c), consensus (50c) 11/09/21 Compass Pathways reports Q3 EPS (38c), consensus (49c)
On The Fly
Show Hide Related Items >> <<
02/28/22 Zynerba announces EC grants orphan drug designation for Zygel 02/28/22 Zynerba announces completion of enrollment in Phase 2 trial of Zygel 02/15/22 Zynerba Chief Legal Officer Hanlon to retire, appoints Parker to position 11/22/21 Zynerba announces issuance of new patent in EU for Zygel 03/09/22 TerrAscend to close Gage Growth acquisition on March 10 01/05/22 TerrAscend appoints Ziad Ghanem as president, COO 11/15/21 Gage Growth receives final court approval for acquisition by TerrAscend 04/12/22 HEXO, Tilray enter agreement for strategic alliance 04/12/22 Tilray enters agreement with HEXO related to Senior Secured Convertible Note 04/06/22 Tilray subsidiary Manitoba Harvest partners with Whole Foods Market 04/05/22 Tilray announces Solei brand launches cannabis edible in Quebec 03/22/22 Tilt appoints Lynn Ricci as VP, investor relations, corporate communications 12/28/21 Trulieve appoints Steve White as president, Nicole Stanton as general counsel 12/28/21 Trulieve Cannabis acquires PurpleMed Healting Center in Arizona 11/29/21 Trulieve Cannabis issues first inaugural ESG report RLMD Relmada Therapeutics 02/23/22 Relmada Therapeutics announces results from REL-1017 HAP study 12/22/21 Relmada Therapeutics: REL-1017 Phase 2 results published in AJOP IIPR Innovative Industrial Properties 04/14/22 Innovative Industrial 'an inflated cannabis bank,' short-seller Blue Orca says 04/14/22 Innovative Industrial Properties down 2% after named as short idea by Blue Orca 04/07/22 Innovative Industrial Properties announces Q1 operating activity 02/10/22 Innovative Industrial Properties buys 114K sqf property in NJ for $35.4M IGC India Globalization Capital 12/08/21 India Globalization Capital says IGC-AD1 ph 1 trial provided 'valuable insight' 12/02/21 India Globalization Capital presents findings from Phase 1 trial of IGC-AD1 GTBIF Green Thumb Industries 04/11/22 Green Thumb Industries to open RISE Mankato on April 14 03/11/22 Green Thumb Industries announces departure of Moore from board of directors 02/08/22 Green Thumb Industries appoints Dorri McWhorter to board of directors 02/28/22 Goodness Growth launches full line of cannabis flower in Minnesota 02/01/22 Verano Holdings to acquire Goodness Growth in $413M all-share transaction 04/14/22 Delta 9 Cannabis enters into agreement with Manitoba 03/31/22 Delta 9 Cannabis closes acquisition of Uncle Sam's Cannabis assets 10/27/21 Delic Holdings announces partnership with GT Research 03/08/22 CV Sciences adds +PlusCBD Relief Softgels to its Wellness line 01/11/22 CV Sciences launches +PlusCBD Pain Relief topicals 01/05/22 CV Sciences announces new distribution agreement with GNC 11/15/21 CV Sciences announces convertible note financing 04/12/22 Curaleaf signs new distribution agreement with WB Canna Co. & Wellness 03/14/22 Curaleaf names Neil Davidson as interim CFO 02/10/22 Curaleaf, Leaf Trade announce partnership 02/07/22 PA Department of Health recalls some vaporized medical marijuana products 01/06/22 CannTrust reports implementation of CCAA plan, settlement of lawsuits 03/21/22 Cronos Group founder Mike Gorenstein returns as CEO 03/01/22 Cronos Group announces planned exit of Peace Naturals Campus in Ontario 02/18/22 Cronos Group announces strategic realignment for $20M-$25M in savings 02/18/22 Cronos Group completes Audit Committee evaluation 03/24/22 Compass Pathways, partners to launch psychedelic research facility 01/19/22 Compass Pathways announces results from survey conducted with Sermo on TRD 01/04/22 Compass Pathways announces results from phase I study on COMP360 12/17/21 Compass Pathways to be added to Nasdaq Biotechnology Index 03/31/22 Canopy Growth appoints Judy Hong as CFO, Jonathan Di Tosto as COO 03/22/22 Canopy Growth announces results from trial using CBD on menstrual symptoms 02/09/22 Canopy Growth reports Q3 total total global cannabis net revenue down 20% y/y 12/15/21 Canopy Growth divests pharmaceutical C3 Cannabinoid Compound Company 03/30/22 Atai Life Sciences reports Q4 net loss $88.9M vs. $86.6M a year ago 02/01/22 IntelGenx receives third loan tranche from Atai Life Sciences 01/27/22 Atai Life Sciences to partner with Dalriada 01/12/22 atai Life Sciences' IND for PCN-101 approved by FDA 03/22/22 Aurora Cannabis to acquire Thrive Cannabis for $38M 02/10/22 Aurora Cannabis reaffirms goal of adjusted EBITDA profitability by 1H2023 02/03/22 Aurora Cannabis' Reliva launches new product line, KG7 12/14/21 Aurora Cannabis and 22nd Century sign license agreement with Cronos Group IGC India Globalization Capital 04/01/22 Alliance Global Partners Senate remains the hurdle for MORE Act, says Alliance Global Partners 06/25/21 Alliance Global Partners Cannabis selloff brings buying opportunities, says Alliance Global IIPR Innovative Industrial Properties 01/14/22 Piper Sandler Innovative Industrial price target lowered to $285 from $290 at Piper Sandler 11/04/21 JMP Securities Innovative Industrial Properties price target raised to $300 from $260 at JMP Securities 09/08/21 Compass Point NewLake Capital Partners initiated with a Buy at Compass Point 09/01/21 BTIG Innovative Industrial Properties price target raised to $290 from $245 at BTIG 02/09/22 Clarus TerrAscend price target lowered to C$14 from C$16.25 at Clarus 12/08/21 Cantor Fitzgerald TerrAscend price target raised to $7.65 from $6.70 at Cantor Fitzgerald 11/17/21 Stifel TerrAscend price target lowered to C$21 from C$23 at Stifel 11/01/21 Stifel TerrAscend price target lowered to C$23 from C$25 at Stifel 03/07/22 Stifel Curaleaf price target lowered to C$25 from C$31 at Stifel 03/04/22 Alliance Global Partners Curaleaf price target lowered to C$15 from C$21 at Alliance Global Partners 02/25/22 Benchmark Curaleaf initiated with a Buy at Benchmark 02/07/22 Alliance Global Partners Cannabis operators in PA could see near-term impact to sales, says AGP FFLWF Fire & Flower Holdings 12/15/21 Stifel Fire & Flower Holdings downgraded to Speculative Buy from Buy at Stifel 11/23/21 Cantor Fitzgerald Fire & Flower Holdings initiated with an Overweight at Cantor Fitzgerald 11/22/21 Cantor Fitzgerald Fire & Flower initiated with an Overweight at Cantor Fitzgerald 02/11/22 Cantor Fitzgerald Aurora Cannabis price target lowered to C$7.60 from C$10.75 at Cantor Fitzgerald 02/03/22 CIBC Aurora Cannabis price target lowered to C$6.50 from C$9.25 at CIBC 11/11/21 Canaccord Aurora Cannabis price target lowered to C$6 from C$6.50 at Canaccord 04/04/22 Morgan Stanley Constellation Brands price target lowered to $294 from $299 at Morgan Stanley 03/22/22 Barclays Canopy Growth downgraded to Underweight from Equal Weight at Barclays 03/01/22 Barclays Canopy Growth price target lowered to $9 from $14 at Barclays 03/22/22 Barclays Cronos Group upgraded to Equal Weight from Underweight at Barclays 03/21/22 Stifel Stifel takes neutral overall view of Cronos' CEO transition 03/07/22 Piper Sandler Cronos Group price target lowered to $3 from $4 at Piper Sandler 02/01/22 Craig-Hallum Goodness Growth downgraded to Hold from Buy at Craig-Hallum 11/11/21 Canaccord Goodness Growth price target lowered to C$2.75 from C$4.50 at Canaccord GTBIF Green Thumb Industries 03/02/22 Canaccord Green Thumb Industries price target lowered to C$43 from C$46 at Canaccord 03/02/22 Stifel Green Thumb Industries price target lowered to C$73 from C$80 at Stifel 03/02/22 Craig-Hallum Green Thumb Industries price target lowered to $35 from $40 at Craig-Hallum 04/06/22 MKM Partners Tilray margins contracted despite cost savings, says MKM Partners 04/06/22 Benchmark Tilray fiscal Q3 results 'disappointing,' says Benchmark 03/17/22 Piper Sandler Tilray price target lowered to $6 from $8 at Piper Sandler 03/31/22 Canaccord Trulieve Cannabis price target lowered to C$65 from C$70 at Canaccord 03/30/22 Alliance Global Partners Trulieve Cannabis price target lowered to C$60 from C$76 at Alliance Global Partners 03/29/22 Cantor Fitzgerald Trulieve Cannabis price target lowered to $60 from $72 at Cantor Fitzgerald 05/06/21 Cantor Fitzgerald Zynerba price target raised to $8 from $6 at Cantor Fitzgerald 04/01/22 Canaccord Atai Life Sciences price target lowered to $27 from $28 at Canaccord 03/31/22 RBC Capital Atai Life Sciences price target lowered to $9 from $12 at RBC Capital 11/30/21 Fly Intel: Top five analyst initiations 11/30/21 Maxim Atai Life Sciences initiated with a Buy at Maxim 02/28/22 Canaccord Compass Pathways price target lowered to $78 from $80 at Canaccord 11/11/21 Roth Capital Atai Life Sciences initiated with a Buy at Roth Capital 11/09/21 Citi Citi says Compass Pathways selloff overdone, ups price target to $70 11/09/21 Cantor Fitzgerald Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald RLMD Relmada Therapeutics 12/20/21 SVB Leerink Relmada Therapeutics price target lowered to $42 from $50 at SVB Leerink 11/17/21 Mizuho Relmada Therapeutics initiated with a Buy at Mizuho 09/30/21 Jefferies Jefferies says Street discounting importance of Relmada's Phase 2 mono MDD study 07/28/21 Truist Relmada Therapeutics price target raised to $90 from $75 at Truist 03/01/22 Zynerba reports Q4 EPS (22c), consensus (26c) 11/15/21 Zynerba reports Q3 EPS (26c), consensus (25c) 04/06/22 Tilray reports Q3 EPS 9c vs. ($1.03) last year 01/10/22 Tilray reports Q2 revenue $155M vs. $129M last year RLMD Relmada Therapeutics 03/23/22 Relmada Therapeutics reports Q4 EPS ($1.80), consensus ($1.83) 11/11/21 Relmada Therapeutics reports Q3 EPS ($2.44), consensus ($1.60) IIPR Innovative Industrial Properties 02/23/22 Innovative Industrial Properties reports Q4 AFFO/share $1.85, one estimate $1.84 11/03/21 Innovative Industrial Properties reports Q3 AFFO $1.71, consensus $1.72 GTBIF Green Thumb Industries 03/01/22 Green Thumb Industries reports Q4 EPS 10c vs. 11c last year 03/31/22 Delta 9 Cannabis reports Q4 EPS (C$0.05) vs. (C$0.01) last quarter 11/15/21 Delta 9 Cannabis reports Q3 EPS (C$0.01) vs. (C$0.04) last quarter 11/15/21 CV Sciences reports Q3 EPS 0c vs. (3c) last year 03/04/22 Curaleaf reports Q4 EPS (4c), three estimates (3c) 11/08/21 Curaleaf reports Q3 EPS (8c) vs. (1c) a year ago 03/01/22 Cronos Group reports 2021 EPS ($1.07), consensus (47c) 02/18/22 Cronos Group reports Q3 EPS 21c, consensus (10c) 02/24/22 Compass Pathways reports Q4 EPS (61c), consensus (50c) 11/09/21 Compass Pathways reports Q3 EPS (38c), consensus (49c) 04/07/22 Constellation Brands reports Q4 comparable EPS ex-Canopy losses $2.55 02/09/22 Canopy Growth reports Q3 EPS (C$0.28) vs. (C$2.43) a year ago 11/05/21 Canopy Growth reports Q2 EPS (C$0.03) vs. (C$0.09) a year ago 11/15/21 Atai Life Sciences reports Q3 EPS (21c), consensus (20c) 02/10/22 Aurora Cannabis reports Q2 adjusted EBITDA (C$9M) vs. (C$11.5) in Q1 02/10/22 Aurora Cannabis reports Q2 revenue C$60.6M, vs. C$67.67M a year ago 01/04/22 Aurora Cannabis to deliver C$10M cannabis shipment to Israel 11/09/21 Aurora Cannabis reports Q1 revenue C$60.1M vs. C$67.59M last year